Osimertinib Resistance and EGFR Mutations in NSCLC Treatment
The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation ...
Tag: targeted therapy
Advances in NSCLC Treatment – Overcoming Osimertinib Resistance and Exploring the Potential of Amivantamab and Lazertinib
In the ever-evolving landscape of cancer treatment, recent breakthroughs in the fight against non-small cell lung cancer (NSCLC) have brought ...
POPULAR NEWS
-
NYU Abu Dhabi researchers identify unique survival strategies adopted by fish in the world’s warmest waters
-
CHOP experts describe types of rashes associated with MIS-C
-
Scientists discover that a protein associated with neurodegenerative diseases is also linked to childhood brain cancer
-
Automatic design of metaheuristics: The future of optimization?